# **QUANTITY LIMIT CRITERIA**

DRUG CLASS ANTIEMETICS

BRAND NAME (generic)

**ALOXI INJECTION** 

(palonosetron hydrochloride)

(palonosetron hydrochloride injection)

Status: CVS Caremark Criteria

Type: Quantity Limit

#### **POLICY**

#### FDA-APPROVED INDICATIONS

# **Aloxi Injection**

Chemotherapy-Induced Nausea and Vomiting in Adults

Aloxi is indicated for:

- Moderately emetogenic cancer chemotherapy prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
- Highly emetogenic cancer chemotherapy prevention of acute nausea and vomiting associated with initial and repeat courses

<u>Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Aged 1 Month to Less than 17 Years</u>

Aloxi is indicated for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.

#### Postoperative Nausea and Vomiting in Adults

Aloxi is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.

As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, Aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low.

### **Palonosetron Hydrochloride Injection**

Chemotherapy-Induced Nausea and Vomiting in Adults

Palonosetron Hydrochloride (HCI) Injection is indicated for:

- Moderately emetogenic cancer chemotherapy prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
  - Highly emetogenic cancer chemotherapy prevention of acute nausea and vomiting associated with initial and repeat courses

#### **REFERENCES**

- 1. Aloxi Injection [package insert]. Woodcliff Lake, NJ: Eisai, Inc.; December 2015.
- 2. Palonosetron Hydrochloride [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals, Inc; December 2018.
- 3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. http://online.lexi.com/. Accessed January 2019.

Aloxi Limit Policy 10-H 01-2019

© 2019 Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

- 4. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com/. Accessed January 2019.
- 5. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Onc* 2017; 35:3240-3261.
- 6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.3.2018. Available at: www.nccn.org. Accessed January 2019.

## **LIMIT CRITERIA**

Drug 4 Weeks Limit and 12 Weeks Limit\*

Aloxi Injection 0.25 mg/5 mL (Palonosetron HCI Injection) 10 mL / 21 days

Palonosetron HCl Injection 0.25 mg/2 mL 4 mL / 21 days

<sup>\*</sup> This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit. The duration of 21 days is used for a 28-day fill period.